These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31298380)

  • 41. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
    Chen JM; Bai JY; Yang KX
    IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
    [TBL] [Abstract][Full Text] [Related]  

  • 42. miRNA expression patterns in chemoresistant breast cancer tissues.
    Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
    Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Knockdown of lncRNA FOXD2-AS1 Inhibits Proliferation, Migration, and Drug Resistance of Breast Cancer Cells.
    Nong Q; Yu S; Hu H; Hu X
    Comput Math Methods Med; 2021; 2021():9674761. PubMed ID: 34873418
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induced expression of AMOT reverses adriamycin resistance in breast cancer cells.
    Zhang H; Wang Y; Gao Y; Du M; Pan E; Sun M; Zhang X
    Cell Biol Int; 2024 Sep; 48(9):1301-1312. PubMed ID: 39021301
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.
    Ciardiello F; Caputo R; Borriello G; Del Bufalo D; Biroccio A; Zupi G; Bianco AR; Tortora G
    Int J Cancer; 2002 Mar; 98(3):463-9. PubMed ID: 11920601
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dioscin strengthens the efficiency of adriamycin in MCF-7 and MCF-7/ADR cells through autophagy induction: More than just down-regulation of MDR1.
    Wang C; Huo X; Wang L; Meng Q; Liu Z; Liu Q; Sun H; Sun P; Peng J; Liu K
    Sci Rep; 2016 Jun; 6():28403. PubMed ID: 27329817
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 7-O-geranylquercetin contributes to reverse P-gp-mediated adriamycin resistance in breast cancer.
    Zhang E; Liu J; Shi L; Guo X; Liang Z; Zuo J; Xu H; Wang H; Shu X; Huang S; Zhang S; Kang X; Zhen Y
    Life Sci; 2019 Dec; 238():116938. PubMed ID: 31593704
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response.
    Lin S; Yu L; Song X; Bi J; Jiang L; Wang Y; He M; Xiao Q; Sun M; Olopade OI; Zhao L; Wei M
    Cell Death Dis; 2019 Sep; 10(9):666. PubMed ID: 31511498
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination of 7-
    Chen Y; Li X; Shi L; Ma P; Wang W; Wu N; Gan Y; Han X; Huang S; Kang X; Liu S; Zhen Y
    Aging (Albany NY); 2022 Sep; 14(17):7156-7169. PubMed ID: 36107024
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
    Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
    Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells.
    Feng R; Dong L
    Int J Clin Exp Pathol; 2015; 8(6):6107-16. PubMed ID: 26261488
    [TBL] [Abstract][Full Text] [Related]  

  • 52. miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A.
    Zhang Y; He Y; Lu LL; Zhou ZY; Wan NB; Li GP; He X; Deng HW
    Kaohsiung J Med Sci; 2019 Jan; 35(1):17-23. PubMed ID: 30844143
    [TBL] [Abstract][Full Text] [Related]  

  • 53. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1.
    Yang X; Hu Q; Hu LX; Lin XR; Liu JQ; Lin X; Dinglin XX; Zeng JY; Hu H; Luo ML; Yao HR
    Discov Med; 2017 Sep; 24(131):75-85. PubMed ID: 28972876
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1).
    Zhao L; Wang Y; Jiang L; He M; Bai X; Yu L; Wei M
    J Exp Clin Cancer Res; 2016 Feb; 35():25. PubMed ID: 26842910
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel microtubule inhibitor SQ overcomes multidrug resistance in MCF-7/ADR cells by inhibiting BCRP function and mediating apoptosis.
    Chang X; Liu Z; Cao S; Bian J; Zheng D; Wang N; Guan Q; Wu Y; Zhang W; Li Z; Zuo D
    Toxicol Appl Pharmacol; 2022 Feb; 436():115883. PubMed ID: 35031325
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Psoralen reverses the P-glycoprotein-mediated multidrug resistance in human breast cancer MCF-7/ADR cells.
    Jiang J; Wang X; Cheng K; Zhao W; Hua Y; Xu C; Yang Z
    Mol Med Rep; 2016 Jun; 13(6):4745-50. PubMed ID: 27082231
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells.
    Fang Y; Shen H; Cao Y; Li H; Qin R; Chen Q; Long L; Zhu XL; Xie CJ; Xu WL
    Braz J Med Biol Res; 2014 Jan; 47(1):60-9. PubMed ID: 24519092
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin.
    Qi X; Chang Z; Song J; Gao G; Shen Z
    Anticancer Drugs; 2011 Jul; 22(6):556-62. PubMed ID: 21637162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Shenmai injection suppresses multidrug resistance in MCF-7/ADR cells through the MAPK/NF-κB signalling pathway.
    Yang L; Zhang C; Chen J; Zhang S; Pan G; Xin Y; Lin L; You Z
    Pharm Biol; 2020 Dec; 58(1):276-285. PubMed ID: 32251615
    [No Abstract]   [Full Text] [Related]  

  • 60. microRNA-129-5p suppresses Adriamycin resistance in breast cancer by targeting SOX2.
    Zeng H; Wang L; Wang J; Chen T; Li H; Zhang K; Chen J; Zhen S; Tuluhong D; Li J; Wang S
    Arch Biochem Biophys; 2018 Aug; 651():52-60. PubMed ID: 29802821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.